We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 2

Figure 2. From: Allogeneic Marrow Transplantation in Patients With Severe Systemic Sclerosis.

Skin remodeling in systemic sclerosis (SSc) patients after allogeneic hematopoietic cell transplantation (HCT) following myeloablative conditioning. The skin biopsy sample obtained from patient 1 before HCT shows extensive collagen deposits in the dermis. At 5 years after allogeneic HCT, a skin biopsy sample taken from a site adjacent to the pretransplant biopsy site shows complete resolution of the dermal fibrosis, consistent with the occurrence of skin “remodeling.” (Original magnification × 40.)

Richard A. Nash, et al. Arthritis Rheum. ;54(6):1982-1986.
2.
Figure 1

Figure 1. From: Allogeneic Marrow Transplantation in Patients With Severe Systemic Sclerosis.

Pulmonary and cardiac function, skin scores, and physical function after allogeneic hematopoietic cell transplantation (HCT) following myeloablative conditioning in 2 patients with severe systemic sclerosis (SSc). A, Pulmonary and cardiac function remained stable or improved after allogeneic HCT. Patient 1 was followed up for 5 years after allogeneic HCT and had significant improvement in forced vital capacity (FVC), and her diffusing capacity for carbon monoxide corrected for hemoglobin (DLCOadj) remained stable. Patient 2 did not have pulmonary function tests after the 3-month evaluation posttransplantation. Both patients experienced decreases in DLCOadj during the first 3 months after HCT. The observed improvement in FVC in patient 1 is likely related to the nearly complete resolution of the scleroderma. Ej Fr = ejection fraction. B, The modified Rodnan skin thickness score and physical function, as measured by the Disability Index (DI) of the modified Health Assessment Questionnaire (M-HAQ), improved in both SSc patients after allogeneic HCT. The improvements in function documented by the M-HAQ DI after allogeneic HCT in both SSc patients are likely related to the decrease in the extent of scleroderma.

Richard A. Nash, et al. Arthritis Rheum. ;54(6):1982-1986.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk